We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

84 hedge funds and large institutions have $719M invested in Adverum Biotechnologies in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 29 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 7

107% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 14

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

72% more capital invested

Capital invested by funds: $419M → $719M (+$300M)

45% more funds holding

Funds holding: 58 → 84 (+26)

Holders
84
Holders Change
+26
Holders Change %
+44.83%
% of All Funds
2.24%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
34
Increased
29
Reduced
14
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$11M
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.7M
3
FCM
Frontier Capital Management
Massachusetts
+$4.74M
4
Millennium Management
Millennium Management
New York
+$4.4M
5
SM
Sabby Management
Florida
+$3.58M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$16.7M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.15M
3
Marshall Wace
Marshall Wace
United Kingdom
-$1.55M
4
PRCM
Pine River Capital Management
Minnesota
-$998K
5
UBS AM
UBS AM
Illinois
-$985K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
76
Legal & General Group
United Kingdom
$17K +$11.9K +31 New
Wells Fargo
77
Wells Fargo
California
$17K +$12.3K +32 New
TRCT
78
Tower Research Capital (TRC)
New York
$16K +$3.85K +10 +50%
BlackRock
79
BlackRock
New York
$11K – – –
SM
80
Sabby Management
Florida
$7.71K +$3.58M +9,280 +186%
RNS
81
Robert N. Shapiro
$6K +$3.85K +10 New
Lazard Asset Management
82
Lazard Asset Management
New York
$5K +$4.24K +11 New
PNC Financial Services Group
83
PNC Financial Services Group
Pennsylvania
$1K +$385 +1 New
Manulife (Manufacturers Life Insurance)
84
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$266 +$190K +493 New
Marshall Wace
85
Marshall Wace
United Kingdom
– -$1.55M -4,541 Closed
UBS AM
86
UBS AM
Illinois
– -$985K -2,880 Closed
LOAMU
87
Lombard Odier Asset Management (USA)
New York
– -$854K -2,499 Closed
RSCM
88
Rock Springs Capital Management
Maryland
– -$246K -720 Closed
D.E. Shaw & Co
89
D.E. Shaw & Co
New York
– -$203K -595 Closed
BG
90
BlackRock Group
United Kingdom
– -$167K -489 Closed
SSG
91
Summit Securities Group
New York
– -$16K -48 Closed
1 2 3
4

ADVM Hedge Fund Activity: Q4 2014 in Review

84 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2014, worth a combined $719M — up 72% from $419M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ADVM positions and 7 closed out — a net gain of 27 holders — while 29 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $11M. The largest seller was Deerfield Management, cutting an estimated $16.7M.

  • 84 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2014, up from 58 in Q3 2014.
  • Funds reported $719M of Adverum Biotechnologies stock for Q4 2014, up 72% quarter-over-quarter.
  • 34 funds opened new Adverum Biotechnologies positions in Q4 2014 and 7 closed out, a net change of +27 holders.
  • The largest Adverum Biotechnologies buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $11M added.
  • The largest Adverum Biotechnologies seller in Q4 2014 was Deerfield Management, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2014.